Biovail Corporation

Biovail Corporation

March 30, 2005 14:08 ET

Biovail to Present at the Smith Barney Citigroup 2005 Healthcare Conference




MARCH 30, 2005 - 14:08 ET

Biovail to Present at the Smith Barney Citigroup 2005
Healthcare Conference

TORONTO--(CCNMatthews - Mar 30, 2005) -

Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced that the
Company will present at The Smith Barney Citigroup 2005 Healthcare
Conference, at the Mayflower Hotel in Washington, D.C.

Biovail's presentation is scheduled for Thursday, March 31, 2005 at
11:30 a.m. EST. A live and archived Web cast will be available on the
Investor Relations page of Biovail's Web site,

About Biovail Corporation

Biovail Corporation is an international full-service pharmaceutical
company, engaged in the formulation, clinical testing, registration,
manufacture, sale and promotion of pharmaceutical products utilizing
advanced drug-delivery technologies. For more information about Biovail,
visit the company's Web site at

For further information, please contact Ken Howling at 905-286-3000 or
send inquiries to

"Safe Harbor" Statement Under the Private Securities Litigation Reform
Act of 1995

To the extent any statements made in this release contain information
that is not historical, these statements are forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. We have based these forward-looking statements on our current
expectations and projections about future events. Our actual results
could differ materially from those discussed in, or implied by, these
forward-looking statements. Forward-looking statements are identified by
words such as "believe", "anticipate", "expect", "intend", "plan",
"will", "may" and other similar expressions. In addition, any statements
that refer to expectations, projections or other characterizations of
future events or circumstances are forward-looking statements.
Forward-looking statements include, but are not necessarily limited to,
risks and uncertainties, including the difficulty of predicting U.S.
Food and Drug Administration ("FDA") and Canadian Therapeutic Products
Directorate ("TPD") approvals, acceptance and demand for new
pharmaceutical products, the impact of competitive products and pricing,
new product development and launch, reliance on key strategic alliances,
availability of raw materials and finished products, third parties, the
regulatory environment, fluctuations in operating results and other
risks detailed from time to time in the company's filings with the
Securities and Exchange Commission ("SEC") and the Ontario Securities
Commission ("OSC"). Biovail Corporation undertakes no obligation to
update or revise any forward-looking statement.


Contact Information

    Biovail Corporation
    Kenneth G. Howling, 905-286-3000